Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. more
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -5.19% | -0.81% |
| 1-Month Return | -13.39% | -0.04% |
| 3-Month Return | -12.16% | 3.81% |
| 6-Month Return | 19.4% | 21.7% |
| 1-Year Return | 70.59% | 15.88% |
| 3-Year Return | 135.38% | 79.6% |
| 5-Year Return | -1% | 76.69% |
| 10-Year Return | 99.08% | 255.31% |
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -93.79% | -34.56% |
| 1-Month Return | -82.61% | -0.49% |
| 3-Month Return | -40.89% | 16.37% |
| 6-Month Return | 43.27% | 48.92% |
| 1-Year Return | 70.59% | 15.88% |
| 3-Year Return | 33.02% | 21.55% |
| 5-Year Return | -0.20% | 12.06% |
| 10-Year Return | 7.13% | 13.52% |
| Stock name | Ticker | Weight |
|---|---|---|
AbCellera Biologics Inc | ABCL | 1.76% |
Amylyx Pharmaceuticals Inc | AMLX | 1.5% |
First Tracks Biotherapeutics Inc | TRAX | 1.48% |
Xencor Inc | XNCR | 1.41% |
4D Molecular Therapeutics Inc | FDMT | 1.21% |
ORIC Pharmaceuticals Inc | ORIC | 1.16% |
MBX Biosciences Inc | MBX | 1.14% |
Adlai Nortye Group Ltd | ANL | 1.12% |
SELLAS Life Sciences Group Inc | SLS | 1.11% |
SpyGlass Pharma Inc | SGP | 1.09% |
Monopar Therapeutics Inc | MNPR | 1.08% |
Definium Therapeutics Inc | DFTX | 1.08% |
Replimune Group Inc | REPL | 1.03% |
Achieve Life Sciences Inc | ACHV | 1.03% |
Nurix Therapeutics Inc | NRIX | 1.02% |
uniQure NV | QURE | 1.01% |
Zenas Biopharma Inc | ZBIO | 1.01% |
Immix Biopharma Inc | IMMX | 1.01% |
Candel Therapeutics Inc | CADL | 0.98% |
Kymera Therapeutics Inc | KYMR | 0.98% |
Palvella Therapeutics Inc | PVLA | 0.98% |
LB Pharmaceuticals Inc | LBRX | 0.97% |
Revolution Medicines Inc | RVMD | 0.95% |
Generate Biomedicines Inc | GENB | 0.94% |
Vor BioPharma Inc | VOR | 0.93% |
Viking Therapeutics Inc | VKTX | 0.93% |
Ideaya Biosciences Inc | IDYA | 0.92% |
Alto Neuroscience Inc | ANRO | 0.92% |
Viridian Therapeutics Inc | VRDN | 0.92% |
Vir Biotechnology Inc | VIR | 0.91% |
Recursion Pharmaceuticals Inc | RXRX | 0.9% |
Janux Therapeutics Inc | JANX | 0.9% |
Belite Bio Inc | BLTE | 0.89% |
Oruka Therapeutics Inc | ORKA | 0.89% |
Immunome Inc | IMNM | 0.88% |
VeraDermics Inc | MANE | 0.88% |
Vaxcyte Inc | PCVX | 0.87% |
Relay Therapeutics Inc | RLAY | 0.87% |
Invivyd Inc | IVVD | 0.86% |
Edgewise Therapeutics Inc | EWTX | 0.86% |
Biohaven Ltd | BHVN | 0.85% |
Summit Therapeutics Inc | SMMT | 0.85% |
Altimmune Inc | ALT | 0.85% |
GH Research PLC | GHRS | 0.84% |
CG oncology Inc | CGON | 0.84% |
MeiraGTx Holdings plc | MGTX | 0.84% |
Arbutus Biopharma Corp | ABUS | 0.83% |
Cullinan Therapeutics Inc | CGEM | 0.82% |
Mineralys Therapeutics Inc | MLYS | 0.82% |
Design Therapeutics Inc | DSGN | 0.81% |
Prime Medicine Inc | PRME | 0.81% |
Dianthus Therapeutics Inc | DNTH | 0.8% |
Sana Biotechnology Inc | SANA | 0.8% |
Scholar Rock Holding Corp | SRRK | 0.8% |
Maze Therapeutics Inc | MAZE | 0.79% |
Inhibrx Biosciences Inc | INBX | 0.79% |
REGENXBIO Inc | RGNX | 0.79% |
Compass Pathways Plc | CMPS | 0.79% |
Spyre Therapeutics Inc | SYRE | 0.78% |
Pharvaris NV | PHVS | 0.78% |
Neurogene Inc | NGNE | 0.78% |
Avalo Therapeutics Inc | AVTX | 0.78% |
Septerna Inc | SEPN | 0.77% |
Praxis Precision Medicines Inc | PRAX | 0.77% |
Arcus Biosciences Inc | RCUS | 0.77% |
Solid Biosciences Inc | SLDB | 0.76% |
Climb Bio Inc | CLYM | 0.76% |
Erasca Inc | ERAS | 0.75% |
Assembly Biosciences Inc | ASMB | 0.75% |
Arvinas Inc | ARVN | 0.75% |
ProKidney Corp | PROK | 0.75% |
Immunovant Inc | IMVT | 0.74% |
Prothena Corp PLC | PRTA | 0.73% |
Celldex Therapeutics Inc | CLDX | 0.73% |
Intellia Therapeutics Inc | NTLA | 0.73% |
Nektar Therapeutics | NKTR | 0.73% |
Corvus Pharmaceuticals Inc | CRVS | 0.72% |
ArriVent Biopharma Inc | AVBP | 0.72% |
Rezolute Inc | RZLT | 0.72% |
Enliven Therapeutics Inc | ELVN | 0.71% |
Rocket Pharmaceuticals Inc | RCKT | 0.71% |
Disc Medicine Inc | IRON | 0.71% |
Damora Therapeutics Inc | DMRA | 0.71% |
Kodiak Sciences Inc | KOD | 0.71% |
Vera Therapeutics Inc | VERA | 0.71% |
Lexicon Pharmaceuticals Inc | LXRX | 0.7% |
Savara Inc | SVRA | 0.7% |
Jade Biosciences Inc | JBIO | 0.7% |
Aura Biosciences Inc | AURA | 0.7% |
Cogent Biosciences Inc | COGT | 0.69% |
AnaptysBio Inc | ANAB | 0.67% |
Bicycle Therapeutics PLC | BCYC | 0.67% |
Olema Pharmaceuticals Inc | OLMA | 0.67% |
CytomX Therapeutics Inc | CTMX | 0.66% |
Bicara Therapeutics Inc | BCAX | 0.66% |
Dyne Therapeutics Inc | DYN | 0.66% |
Celcuity Inc | CELC | 0.65% |
Aktis Oncology Inc | AKTS | 0.65% |
Immatics NV | IMTX | 0.65% |
Rapport Therapeutics Inc | RAPP | 0.64% |
Allogene Therapeutics Inc | ALLO | 0.64% |
Beam Therapeutics Inc | BEAM | 0.62% |
Oculis Holding AG | OCS | 0.62% |
Stoke Therapeutics Inc | STOK | 0.62% |
Upstream Bio Inc | UPB | 0.62% |
Structure Therapeutics Inc | GPCR | 0.61% |
Taysha Gene Therapies Inc | TSHA | 0.61% |
Tyra Biosciences Inc | TYRA | 0.6% |
Annexon Inc | ANNX | 0.59% |
Tectonic Therapeutic Inc | TECX | 0.58% |
Tango Therapeutics Inc | TNGX | 0.58% |
Crescent Biopharma Inc | CBIO | 0.58% |
Lexeo Therapeutics Inc | LXEO | 0.56% |
Newamsterdam Pharma Co NV | NAMS | 0.54% |
Xenon Pharmaceuticals Inc | XENE | 0.53% |
Cabaletta Bio Inc | CABA | 0.52% |
Wave Life Sciences Inc | WVE | 0.49% |
MoonLake Immunotherapeutics | MLTX | 0.47% |
Monte Rosa Therapeutics Inc | GLUE | 0.47% |
Relmada Therapeutics Inc | RLMD | 0.42% |
Compass Therapeutics Inc | CMPX | 0.41% |
BridgeBio Oncology Therapeutics Inc | BBOT | 0.37% |
Evommune Inc | EVMN | 0.32% |
BioAge Labs Inc | BIOA | 0.29% |
MapLight Therapeutics Inc | MPLT | 0.28% |
Capricor Therapeutics Inc | CAPR | 0.24% |
Alumis Inc | ALMS | 0.22% |
EyePoint Inc | EYPT | 0.2% |
Sionna Therapeutics Inc | SION | 0.11% |
Cash/Cash equivalents | Cash.Cash.equivalents | 0.07% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
Virtus LifeSci Biotech Clinical Trials ETF (BBC) share price today is $46.1252.
Yes, Indians can buy shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. To buy BBC from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. You can start investing in Virtus LifeSci Biotech Clinical Trials ETF (BBC) with a minimum investment of $1.
The 52-week high price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $56.18. The 52-week low price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $26.13.
The stock symbol (or ticker) of Virtus LifeSci Biotech Clinical Trials ETF is BBC.
Yes, you can setup SIP in Virtus LifeSci Biotech Clinical Trials ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of BBC on the Vested app.
The expense ratio of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is 0.79%.
Link copied